BrandEseence Logo

Covid-19 Medicine Market

Covid-19 Medicine Market Size, Share & Trends Analysis Report

Covid-19 Medicine Market Size Share Companies & Trends Analysis Report By Drug Type (Remdesivir, Hydroxychloroquine, Chloroquine, Others {Anti Viral, Multivitamins, Corticosteroids And Others}) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others (ACC)) Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2029

Published
Report ID : BMRC 1474
Number of pages : 300
Published Date : Jan 2023
Category : Healthcare
Delivery Timeline : 48 hrs

Industry Insights-

  • The Global Covid-19 Medicine Market was valued at USD 1782.4 Million in 2021
  • It is anticipated to reach USD 32.2 Million in 2028
  • A CAGR of -52.6% is anticipated over the forecast period

Market Overview-

Coronaviruses cause respiratory tract infections in humans that can only cause common cold and others that cause severe respiratory problem and ultimately death. As Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus i.e., SARS-CoV-2, which has spread rapidly throughout the world and in March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic. This pandemic has severely weakened health systems & economic and social progress globally. While countries, have taken strong measures to cover the spread of COVID-19 through better diagnostics and treatment, the coronavirus medicine may provide an effective solution by enhancing immunity and controlling the disease spread.

Key Players-

Some of the key players for global Covid-19 Medicine Market are

  • Gilead Sciences Inc.
  • IPCA
  • Zydus Cadila
  • I-Mab Biopharma
  • Airway Therapeutics
  • Tiziana Life Sciences
  • OyaGen
  • BeyondSpring
  • Algernon Pharmaceuticals
  • Grifols
  • Johnson & Johnson
  • Eli Lilly
  • Tonix Pharmaceuticals
  • Novartis
  • Roche
  • ImmunoPrecise Antibodies
  • others

Segmentation Analysis-

By Drug Type

  • Remdesivir
  • Hydroxychloroquine, Chloroquine
  • Others (Other Anti Viral, Multivitamins, Corticosteroids and Others)

The drug type segment of covid-19 medicine market is dominated by Remdesivir with the largest market share of 75.83% in 2020.

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others (ACC)

The distribution channel segment of covid-19 medicine market report is dominated by Hospital Pharmacies segment by capturing the largest market of 74.82 % in year 2020

By Region:

  • North America

    • U.S.
    • Canada
  • Europe

    • U.K.
    • France
    • Germany
    • Italy
  • Asia Pacific

    • China
    • Japan
    • India
    • Southeast Asia
  • Latin America

    • Brazil
    • Mexico
  • Middle East and Africa

    • GCC
    • Africa
    • Rest of Middle East and Africa

Geographically, North America region is expected to dominate the global Covid-19 medicine market. This is due to the increasing research & development activities for covid-19 medicine in this region. For instance; on November 11th, 2020 Eli Lilly's Covid-19 antibody drug treatment gets emergency USFDA clearance. The FDA authorized the experimental treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adults, including those who are 65 and older, and pediatric patients.

Eli Lilly & Co.’s antibody therapy was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19, widening access to a treatment that early data suggests is effective in keeping people infected with the coronavirus out of the hospital. The Food and Drug Administration authorized the experimental treatment, called Bamlanivimab, for use against mild-to-moderate Covid-19 in adults, including those who are 65 and older, and pediatric patients, the agency said on its website. Bamlanivimab is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age or older who weigh at least 88 pounds [40 kg]), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. Bamlanivimab is a neutralizing antibody drug. When there’s a virus in their body, like COVID-19, their immune system makes antibodies to fight it off.

Moreover, Europe is expected to show a significant growth in the global Covid-19 medicine market due to large population base, growth in research funding, and exponential registered cases of COVID-19 in this region. For instance; according to a WHO report; on October 4th, 2020; it was estimated that incidence of new cases has continued to increase in the European Region overall. France, the Russian Federation, the United Kingdom, Spain, and Israel reported the highest numbers of new cases in the past week. With over 1.2 million COVID-19 cases, and over 63,000 new cases in the past week (436 cases per 1 million population), the Russia Federation is reporting the second highest number of new cases in Europe and the sixth highest number globally.

Market Drivers-

Increasing demand for the medicine all over the world and rising healthcare expenditures

Factors such as the present coronavirus outbreak which has led to an increasing demand for the medicine all over the world, increasing healthcare expenditures, growing concerns regarding Coronavirus outbreaks at regular intervals and the growing need to protect populations across the globe from known as well as unencountered virus strains are expected to drive the growth of global Covid-19 medicine market.

As the 2019 novel coronavirus (2019-nCoV) was officially named as COVID-19 pandemic by the World Health Organization and spread to more than 180 countries. For instance; according to the World Health Organization; as of February 16th, 2021, India has about 1,09,25710 confirmed cases of COVID-19 and Globally, there are about 10,91,51,283 confirmed COVID-19 cases across 192 counties which has led to about 24,07,688 deaths. Thus, there is increasing demand for medicine for prevention of outbreak.

In addition, as health financing is necessary to the ability of health systems to maintain & improve human welfare and as there is rapid growth in cases of COVID-19, which has challenged national healthcare capacity, testing systems at an advanced ICU and public health infrastructure level to develop the preventive measure for the pandemic. Thus, many of the governments are taking so many efforts and spending more to develop an effective medicine for Covid-19.

Increasing research & development activities for the Covid-19 medicine

Hence increasing healthcare expenditure for Covid-19 medicine is also driving the growth of global covid-19 medicine market. Moreover, increasing research & development activities for the covid-19 medicine is also supplementing the market growth. However, time required for each stage of clinical trials of medicine and high costs associated with research & development of drugs may hamper the market growth. In spite of that, growing investment in research & development to develop more effective Covid-19 medicine may provide an opportunity for the further growth of the market.

Recent Developments-

In recent years, scientists and leading organizations are developing various drugs by using a wide range of techniques some of which are never been approved for medical purposes before and some of which are already well established. While manufacturing, drugs manufacturers are focused on the speedy recovery of patients. To overcome the effects or decrease the risk of coronavirus the number of drug companies are ready to enter the market. Additionally, the increasing number of coronavirus patients is the major factor as well as the concern globally. Coronavirus is adversely impacted all economies worldwide. Following are some drugs that are approved by the government for coronavirus cases in the emergency use:

  • Remdesivir: On 22nd October, 2020; The U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval. The approval of Veklury was supported by the agency’s analysis of data from three randomized, controlled clinical trials that included patients hospitalized with mild-to-severe COVID-19. The FDA has granted an emergency use authorization for the rheumatoid arthritis drug baricitinib to treat COVID-19 in some cases. Baricitinib is a pill that seems to work against COVID-19 by reducing inflammation and having antiviral activity. According to FDA, baricitinib may be used in combination with remdesivir in people who are hospitalized with COVID-19 who are on mechanical ventilators or need supplemental oxygen.
  • Hydroxychloroquine/Chloroquine: Chloroquine and Hydroxychloroquine increase the endosomal pH, inhibiting combination of severe acute respiratory syndrome coronavirus 2 and the host cell membranes. Chloroquine prevents glycosylation of the cellular angiotensin-converting enzyme 2 receptor, which may interfere with the binding of severe acute respiratory syndrome-associated coronavirus to the cell receptor. The US Food and Drug Administration approved limited emergency use for chloroquine and hydroxychloroquine as a treatment for COVID-19. Chloroquine is being tested in various clinical trials conducted by government agencies and academic institutions. Other antivirals drugs are also planned to be fast-tracked for testing for Coronavirus. Hydroxychloroquine and chloroquine have antiviral properties against SARS-CoV-2, the virus that causes COVID-19.
  • Favilavir: On February 21st, 2020; Zhejiang Hisun Pharmaceutical’s anti-viral drug Favilavir (Favipiravir) has been approved as an investigational therapy to treat the coronavirus, reported by local media. According to media reports, Favilavir has been approved by China as the first antiviral drug against coronavirus. The anti-viral drug Favilavir has been approved by the National Medical Product Treatment Administration of China for the treatment of coronavirus covid-1 treat. Favilavir has been approved for marketing in the treatment of influenza and is one of three drugs that have shown efficacy against coronavirus in human trials. For example, Favipiravir sells under the brand name Avigan and is an approved drug for the treatment of influenza. The drug will be sold under the Brandon Faviton brand and will be available in 200 mg and 400 mg tablets. Pune-based pharmaceutical marketing company Britton Pharmaceuticals is all set to export the anti-viral drug Favpipirvir to one of the countries, awaiting the approval of the Indian Drug Controller to bring the drug to India.
Report Analysis Details
Historical data 2016 - 2021
Forecast Period 2022 - 2029
Market Size in 2021: USD 1782.4 Million
Base year considered 2021
Forecast Period CAGR %: -52.6%
Market Size Expected in 2028: USD 32.2 Million
Tables, Charts & Figures: 175
Pages 300
Key Players/Companies Gilead Sciences, Inc.,IPCA,Zydus Cadila,I-Mab Biopharma,Airway Therapeutics,Tiziana Life Sciences,OyaGen,BeyondSpring,Algernon Pharmaceuticals, Grifols, Johnson & Johnson, Eli Lilly, Tonix Pharmaceuticals, Novartis, Roche, ImmunoPrecise Antibodies, others.
Segments Covered By Drug Type, By Distribution Channel
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
SUMMARY
VishalSawant
Vishal Sawant
Business Development
vishal@brandessenceresearch.com
+91 8830 254 358
Segmentation
Segments

By Drug Type

  • Remdesivir
  • Hydroxychloroquine, Chloroquine
  • Others (Other Anti Viral, Multivitamins, Corticosteroids and Others)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others (ACC)
Country
Regions and Country

North America

  • U.S.
    U.S.
  • Canada
    Canada

Europe

  • Germany
    Germany
  • France
    France
  • U.K.
    U.K.
  • Italy
    Italy
  • Spain
    Spain
  • Sweden
    Sweden
  • Netherlands
    Netherlands
  • Turkey
    Turkey
  • Switzerland
    Switzerland
  • Belgium
    Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
    South Korea
  • Japan
    Japan
  • China
    China
  • India
    India
  • Australia
    Australia
  • Philippines
    Philippines
  • Singapore
    Singapore
  • Malaysia
    Malaysia
  • Thailand
    Thailand
  • Indonesia
    Indonesia
  • Rest of APAC

Latin America

  • Mexico
    Mexico
  • Colombia
    Colombia
  • Brazil
    Brazil
  • Argentina
    Argentina
  • Peru
    Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
    Saudi Arabia
  • UAE
    UAE
  • Egypt
    Egypt
  • South Africa
    South Africa
  • Rest of MEA
Company
Key Players
  • Gilead Sciences Inc.
  • IPCA
  • Zydus Cadila
  • I-Mab Biopharma
  • Airway Therapeutics
  • Tiziana Life Sciences
  • OyaGen
  • BeyondSpring
  • Algernon Pharmaceuticals
  • Grifols
  • Johnson & Johnson
  • Eli Lilly
  • Tonix Pharmaceuticals
  • Novartis
  • Roche
  • ImmunoPrecise Antibodies
  • others

+44-1173181773

sales@brandessenceresearch.com

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com

JOIN US

LONDON OFFICE

BrandEssence® Market Research and Consulting Pvt ltd.

124, City Road, London EC1V 2NX

FOLLOW US

Twitter
Facebook
LinkedIn
Skype
YouTube

CONTACT US

1-888-853-7040 - U.S. (TOLL FREE)
+44-1173181773 - U.K. OFFICE
+91-7447409162 - INDIA OFFICE

© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®

PaymentModes